3,5-二乙氧基苯甲酰氯 | 347913-16-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二乙氧基苯甲酰氯
• 中文别名: 3,5-二乙氧基苯酰氯
• 英文名称: 3,5-diethoxybenzoyl chloride
• CAS: 347913-16-0
• 化学式: C₁₁H₁₃ClO₃
• mdl: MFCD02258022
• 分子量: 228.675
• InChiKey: JHDNGEJBXLHONS-UHFFFAOYSA-N

物化性质

• 熔点：
  70-74 °C(lit.)
• 沸点：
  330.1±22.0 °C(Predicted)
• 密度：
  1.161±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  在常温常压下稳定，应避免与强氧化剂接触，并且尽量减少水分的接触。

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34,R43
• 海关编码：
  2918990090
• WGK Germany：
  3
• 危险品运输编号：
  UN 3261 8/PG 2

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 3,5-Diethoxybenzoyl chloride
CAS-No. : 347913-16-0
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin corrosion (Category 1B)
Respiratory sensitization (Category 1)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Causes burns. May cause sensitization by skin contact.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Danger
Hazard statement(s)
H314 Causes severe skin burns and eye damage.
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Precautionary statement(s)
P261 Avoid breathing dust.
P280 Wear protective gloves/ protective clothing/ eye protection/ face
protection.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
P310 Immediately call a POISON CENTER or doctor/ physician.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R34 Causes burns.
R43 May cause sensitization by skin contact.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36/37/39 Wear suitable protective clothing, gloves and eye/face protection.
S45 In case of accident or if you feel unwell, seek medical advice immediately
(show the label where possible).
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C11H13ClO3
Molecular Weight : 228,67 g/mol
Component Concentration
3,5-Diethoxybenzoyl chloride
CAS-No. 347913-16-0 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Consult a
physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with
water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Cough, Shortness of breath, Headache, Nausea, Vomiting
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Hydrogen chloride gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Handle and store under inert gas.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 70 - 74 °C - lit.
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,697
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Reacts violently with water.
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
May cause sensitization by inhalation.
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Material is extremely destructive to the tissue of
the mucous membranes and upper respiratory tract.
Ingestion May be harmful if swallowed. Causes burns.
Skin May be harmful if absorbed through skin. Causes skin burns.
Eyes Causes eye burns.
Signs and Symptoms of Exposure
Cough, Shortness of breath, Headache, Nausea, Vomiting
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: 3261 IMDG: 3261 IATA: 3261
UN proper shipping name
ADR/RID: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S. (3,5-Diethoxybenzoyl chloride)
IMDG: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S. (3,5-Diethoxybenzoyl chloride)
IATA: Corrosive solid, acidic, organic, n.o.s. (3,5-Diethoxybenzoyl chloride)
Transport hazard class(es)
ADR/RID: 8 IMDG: 8 IATA: 8
Packaging group
ADR/RID: II IMDG: II IATA: II
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,5-二乙氧基苯甲酰氯 在 吡啶 、 氢氧化钾 、 水 、 溶剂黄146 、 肼 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.17h， 生成
  参考文献：
  名称：

  WO2006/124780

  摘要：

  公开号：
• 作为产物：
  描述：

  3,5-二乙氧基苯甲酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成 3,5-二乙氧基苯甲酰氯
  参考文献：
  名称：

  扩展 2-苯基苯并碲唑库：乙氧基官能团对紫外/可见光吸收特性的红移效应

  摘要：

  这项工作描述了在 2 位带有苯环的新型苯并碲唑系列的高产率合成，该苯环被不同的乙氧基链官能化。改变这些官能团的数量和位置决定了固态自组装的差异，以及目标分子的光物理特性。正如对每个分子的 HOMO-LUMO 间隙的理论计算所预期的那样，与未取代的苯并碲唑相比，邻位和对位乙氧基链的存在决定了吸收峰中高达 20 nm 的红移。同样，对于那些带有o的衍生物，在125 Te NMR 光谱的化学位移中观察到更显着的变化。-和对-乙氧基官能化。

  DOI：

  10.1055/s-0041-1737898

文献信息

• N-Substituted homopiperazine barbiturates as gelatinase inhibitors
  作者：Jun Wang、Carlos Medina、Marek W. Radomski、John F. Gilmer

  DOI：10.1016/j.bmc.2011.06.055

  日期：2011.8

  12-O-tetradecanoylphorbol-13-acetate (PMA)-stimulated HT-1080 cells as well as using recombinant human MMPs. N-Acyl homopiperazine compounds were found to be potent inhibitors of the gelatinases (range in nM) and generally more potent than the corresponding piperazine analogues. The panel of N-acyl homopiperazines was enlarged in order to exploit differences between the gelatinases at the S2′ site in order to design

  基质金属蛋白酶涉及广泛的病理生理过程，并且一直在积极寻求针对这些酶的有效选择性抑制剂。5,5-二取代的巴比妥酸盐有希望成为抑制剂，在体内是稳定的，并且对明胶酶（MMP-2和MMP-9）具有相对选择性。在本文中，我们描述了5-哌嗪和-高哌嗪取代的巴比妥酸酯的合成。使用来自12 - O-十四烷酰phorbol-13-乙酸盐（PMA）刺激的HT-1080细胞的上清液以及使用重组人MMP ，评估了这些化合物作为明胶酶抑制剂的活性。ñ发现酰基高哌嗪化合物是明胶酶的有效抑制剂（范围为nM），通常比相应的哌嗪类似物更有效。N-酰基高哌嗪的面板被扩大，以便利用S2'位点的明胶酶之间的差异，以设计MMP-2-或MMP-9-选择性抑制剂。该组化合物表现出一位数的纳摩尔浓度，并且在两种酶之间具有一定的选择性。代表性的有效化合物是癌细胞迁移的有效抑制剂。
• Isosorbide-Based Aspirin Prodrugs: Integration of Nitric Oxide Releasing Groups
  作者：Michael Jones、Iwona Inkielewicz、Carlos Medina、Maria Jose Santos-Martinez、Anna Radomski、Marek W. Radomski、Maeve N. Lally、Louise M. Moriarty、Joanne Gaynor、Ciaran G. Carolan、Denise Khan、Paul O’Byrne、Shona Harmon、Valerie Holland、John M. Clancy、John F. Gilmer

  DOI：10.1021/jm900561s

  日期：2009.11.12

  Aspirin prodrugs and related nitric oxide releasing compounds hold significant therapeutic promise, but they are hard to design because aspirin esterification renders its acetate group very susceptible to plasma esterase mediated hydrolysis. Isosorbide-2-aspirinate-5-salicylate is a true aspirin prodrug in human blood because it can be effectively hydrolyzed to aspirin upon interaction with plasma

  阿司匹林前药和相关的释放一氧化氮的化合物具有重大的治疗前景，但由于阿司匹林的酯化作用使其乙酸酯基非常易受血浆酯酶介导的水解作用，因此难以设计。异山梨醇-2-aspirinate-5-salicylate是人血中真正的阿司匹林前药，因为与血浆BuChE相互作用后，它可以有效地水解为阿司匹林。我们表明，远程5酯的身份决定了阿司匹林是否属于血浆介导的水解产物。通过观察最初的基于异山梨醇酯的阿司匹林释放的要求，我们能够在5位引入硝基氧甲基，同时保持释放阿司匹林的能力。这些化合物中的几种是有效的血小板聚集抑制剂。
• Structure–activity relationships and evaluation of esterified diterpenoid alkaloid derivatives as antiproliferative agents
  作者：Koji Wada、Masuo Goto、Takahiro Shimizu、Nami Kusanagi、Megumi Mizukami、Yuji Suzuki、Kang-Po Li、Kuo-Hsiung Lee、Hiroshi Yamashita

  DOI：10.1007/s11418-019-01331-6

  日期：2019.9

  Several newly synthesized delcosine derivatives (6, 7, 13, 13a, 13b) showed substantial suppressive effects against all human tumor cell lines tested. In contrast, the natural alkaloids (1, 31, 33) showed no effect. Most of the active compounds were delcosine derivatives with two specific substitution patterns—C-1 and C-1,14. In particular, 1-acyldelcosine derivative (5–7) displayed more potency than 1,14-diacyldelcosine

  具有明显化学性质和生物活性的二萜类生物碱经常在乌头，翠雀和Garrya属植物中发现。但是，关于乌头和雀花植物的二萜类生物碱成分的抗增殖作用的报道很少。C-1和delcosine 14个酯化（1）中进行，以提供39个新二萜生物碱衍生物（3 - 14，16 - 29，图3a -图7a，图9A，图13A，13B，14a，14b，16a，17a，24a，35a）。选择的化合物（3 - 14，16 - 29，图3a -图7a，图9A，图13A，13B，14A，14B，16A，17A，24A，35A）评估了针对三到五种人类肿瘤细胞系的抗增殖活性，这些细胞系包括三阴性乳腺癌（TNBC）和过表达多药耐药性（MDR）的P-糖蛋白（P-gp）。几个新合成delcosine衍生物（6，7，13，13A，13B）显示对测试的所有人类肿瘤细胞系显着抑制效果。相反，天然生物碱（1，31，33）显示没有影响。大多数活性
• [EN] TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS D'ACIDE TÉTRAHYDROCYCLOPENTA[B]INDOL-3-YLCARBOXYLIQUE UTILES DANS LE TRAITEMENT DE TROUBLES AUTO-IMMUNS ET INFLAMMATOIRES
  申请人：ARENA PHARM INC

  公开号：WO2009078983A1

  公开（公告）日：2009-06-25

  The present invention relates to certain (1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.

  本发明涉及公式（Ia）中的某些（1,2,4-噁二唑-3-基）-1,2,3,4-四氢环-五氢-苯并[b]吲哚-3-基羧酸衍生物及其药学上可接受的盐，该衍生物具有有用的药理特性，例如作为S1P1受体的激动剂。本发明还提供了含有所述化合物的药物组合物，以及使用所述化合物和组合物治疗S1P1相关疾病的方法，例如银屑病、类风湿性关节炎、克罗恩病、移植排斥反应、多发性硬化症、系统性红斑狼疮、溃疡性结肠炎、I型糖尿病、痤疮、微生物感染或疾病以及病毒感染或疾病。
• [EN] GGA AND GGA DERIVATIVES, COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM<br/>[FR] GGA ET DÉRIVÉS DE GGA, COMPOSITIONS DE CEUX-CI ET PROCÉDÉS POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES, COMPRENANT UNE PARALYSIE, LES COMPRENANT
  申请人：COYOTE PHARMACEUTICALS INC

  公开号：WO2013130654A1

  公开（公告）日：2013-09-06

  This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

  本发明涉及戈芬酯醋酸酯（GGA）衍生物以及在抑制神经细胞死亡、增加神经活性、促进轴突生长和细胞存活能力，以及提高接受GGA或GGA衍生物的受试者的存活率的方法中使用GGA及其异构体和GGA衍生物。